A recent licensing agreement allows Mylan to commercialise Otsuka Novel Products’ Delamanid (Deltyba) product indicated for pulmonary multidrug-resistant tuberculosis (MDR-TB) in low and middle-income countries such as India and South Africa.
Mylan hopes to expand the commercial rights and registration into other high MDR-TB burden countries where Otsuka has not had commercial presence.
Go deeper with GlobalData
Figure 1 shows the current number of drugs in pipeline development for MDR-TB. It shows there are very few in last-stage clinical trials and there is an opportunity for more companies to invest in this area.
Figure 1: Novel Drugs in Pipeline for Multidrug-Resistant Tuberculosis
Source: GlobalData, Pharma Intelligence Center, Deals Database [Accessed August, 2017]
South Africa and India are considered by the World Health Organization (WHO) as the highest burden countries for MDR-TB. Since 2015, Delamanid was added to the WHO’s essential medicines list and received first regulatory approval from the European Medicines Agency (EMA) in 2014. However, from 2005, Otsuka has contributed $450m in funding, and most recently produced an initiative programme for development of MDR-TB to lead the way for therapies on the market.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Related Company Profiles
Viatris Inc
European Medicines Agency (UK)
Otsuka Corp